{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T21:45:47Z","timestamp":1774993547004,"version":"3.50.1"},"reference-count":65,"publisher":"American Association for Cancer Research (AACR)","issue":"14","funder":[{"name":"INSERM, University of Nice Sophia-Antipolis, Fondation pour la Recherche M\u00e9dicale","award":["EQU202003010248"],"award-info":[{"award-number":["EQU202003010248"]}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,7,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Overcoming acquired drug resistance is a primary challenge in cancer treatment. Notably, more than 50% of patients with BRAFV600E cutaneous metastatic melanoma (CMM) eventually develop resistance to BRAF inhibitors. Resistant cells undergo metabolic reprogramming that profoundly influences therapeutic response and promotes tumor progression. Uncovering metabolic vulnerabilities could help suppress CMM tumor growth and overcome drug resistance. Here we identified a drug, HA344, that concomitantly targets two distinct metabolic hubs in cancer cells. HA344 inhibited the final and rate-limiting step of glycolysis through its covalent binding to the pyruvate kinase M2 (PKM2) enzyme, and it concurrently blocked the activity of inosine monophosphate dehydrogenase, the rate-limiting enzyme of de novo guanylate synthesis. As a consequence, HA344 efficiently targeted vemurafenib-sensitive and vemurafenib-resistant CMM cells and impaired CMM xenograft tumor growth in mice. In addition, HA344 acted synergistically with BRAF inhibitors on CMM cell lines in vitro. Thus, the mechanism of action of HA344 provides potential therapeutic avenues for patients with CMM and a broad range of different cancers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Glycolytic and purine synthesis pathways are often deregulated in therapy-resistant tumors and can be targeted by the covalent inhibitor described in this study, suggesting its broad application for overcoming resistance in cancer.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/0008-5472.can-20-2114","type":"journal-article","created":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T13:06:37Z","timestamp":1623071197000},"page":"3806-3821","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Dual Covalent Inhibition of PKM and IMPDH Targets Metabolism in Cutaneous Metastatic Melanoma"],"prefix":"10.1158","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1506-7721","authenticated-orcid":false,"given":"Marwa","family":"Zerhouni","sequence":"first","affiliation":[{"name":"1Universit\u00e9 C\u00f4te d'azur, Nice, France."},{"name":"2Inserm U1065, C3M, Team 2, Nice, France."},{"name":"3Inserm U1065, C3M, Team 12, Nice, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6187-6979","authenticated-orcid":false,"given":"Anthony R.","family":"Martin","sequence":"additional","affiliation":[{"name":"1Universit\u00e9 C\u00f4te d'azur, Nice, France."},{"name":"4Institut de Chimie de Nice UMR 7272, Nice, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathan","family":"Furstoss","sequence":"additional","affiliation":[{"name":"1Universit\u00e9 C\u00f4te d'azur, Nice, France."},{"name":"2Inserm U1065, C3M, Team 2, Nice, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent S.","family":"Gutierrez","sequence":"additional","affiliation":[{"name":"1Universit\u00e9 C\u00f4te d'azur, Nice, France."},{"name":"4Institut de Chimie de Nice UMR 7272, Nice, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilie","family":"Jaune","sequence":"additional","affiliation":[{"name":"1Universit\u00e9 C\u00f4te d'azur, Nice, France."},{"name":"3Inserm U1065, C3M, Team 12, Nice, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nedra","family":"Tekaya","sequence":"additional","affiliation":[{"name":"1Universit\u00e9 C\u00f4te d'azur, Nice, France."},{"name":"3Inserm U1065, C3M, Team 12, Nice, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillaume E.","family":"Beranger","sequence":"additional","affiliation":[{"name":"1Universit\u00e9 C\u00f4te d'azur, Nice, France."},{"name":"3Inserm U1065, C3M, Team 12, Nice, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Abbe","sequence":"additional","affiliation":[{"name":"1Universit\u00e9 C\u00f4te d'azur, Nice, France."},{"name":"3Inserm U1065, C3M, Team 12, Nice, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire","family":"Regazzetti","sequence":"additional","affiliation":[{"name":"1Universit\u00e9 C\u00f4te d'azur, Nice, France."},{"name":"3Inserm U1065, C3M, Team 12, Nice, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hella","family":"Amdouni","sequence":"additional","affiliation":[{"name":"1Universit\u00e9 C\u00f4te d'azur, Nice, France."},{"name":"4Institut de Chimie de Nice UMR 7272, Nice, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0513-7570","authenticated-orcid":false,"given":"Mohsine","family":"Driowya","sequence":"additional","affiliation":[{"name":"1Universit\u00e9 C\u00f4te d'azur, Nice, France."},{"name":"4Institut de Chimie de Nice UMR 7272, Nice, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrice","family":"Dubreuil","sequence":"additional","affiliation":[{"name":"5CRCM, Team Signalisation, H\u00e9matopo\u00ef\u00e8se et M\u00e9canismes de l'Oncogen\u00e8se, Marseille, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9253-4998","authenticated-orcid":false,"given":"Fr\u00e9d\u00e9ric","family":"Luciano","sequence":"additional","affiliation":[{"name":"1Universit\u00e9 C\u00f4te d'azur, Nice, France."},{"name":"2Inserm U1065, C3M, Team 2, Nice, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnaud","family":"Jacquel","sequence":"additional","affiliation":[{"name":"1Universit\u00e9 C\u00f4te d'azur, Nice, France."},{"name":"2Inserm U1065, C3M, Team 2, Nice, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meri K.","family":"Tulic","sequence":"additional","affiliation":[{"name":"1Universit\u00e9 C\u00f4te d'azur, Nice, France."},{"name":"2Inserm U1065, C3M, Team 2, Nice, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Cluzeau","sequence":"additional","affiliation":[{"name":"1Universit\u00e9 C\u00f4te d'azur, Nice, France."},{"name":"2Inserm U1065, C3M, Team 2, Nice, France."},{"name":"6CHU de Nice, Nice, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brendan P.","family":"O'Hara","sequence":"additional","affiliation":[{"name":"7Department of Biochemistry and Molecular Genetics, Northwestern University, Chicago, Illinois."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Issam","family":"Ben-Sahra","sequence":"additional","affiliation":[{"name":"7Department of Biochemistry and Molecular Genetics, Northwestern University, Chicago, Illinois."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thierry","family":"Passeron","sequence":"additional","affiliation":[{"name":"1Universit\u00e9 C\u00f4te d'azur, Nice, France."},{"name":"3Inserm U1065, C3M, Team 12, Nice, France."},{"name":"6CHU de Nice, Nice, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachid","family":"Benhida","sequence":"additional","affiliation":[{"name":"4Institut de Chimie de Nice UMR 7272, Nice, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillaume","family":"Robert","sequence":"additional","affiliation":[{"name":"1Universit\u00e9 C\u00f4te d'azur, Nice, France."},{"name":"2Inserm U1065, C3M, Team 2, Nice, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Auberger","sequence":"additional","affiliation":[{"name":"1Universit\u00e9 C\u00f4te d'azur, Nice, France."},{"name":"2Inserm U1065, C3M, Team 2, Nice, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0943-1304","authenticated-orcid":false,"given":"St\u00e9phane","family":"Rocchi","sequence":"additional","affiliation":[{"name":"1Universit\u00e9 C\u00f4te d'azur, Nice, France."},{"name":"3Inserm U1065, C3M, Team 12, Nice, France."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1086","published-online":{"date-parts":[[2021,6,7]]},"reference":[{"key":"2022061706374151600_bib1","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1158\/2159-8290.CD-13-0617","article-title":"The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma","volume":"4","author":"Van Allen","year":"2014","journal-title":"Cancer Discov"},{"key":"2022061706374151600_bib2","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.cell.2012.06.024","article-title":"A landscape of driver mutations in melanoma","volume":"150","author":"Hodis","year":"2012","journal-title":"Cell"},{"key":"2022061706374151600_bib3","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/j.cell.2015.05.044","article-title":"Genomic classification of cutaneous melanoma","volume":"161","author":"Akbani","year":"2015","journal-title":"Cell"},{"key":"2022061706374151600_bib4","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/nrc.2016.37","article-title":"From melanocytes to melanomas","volume":"16","author":"Shain","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"2022061706374151600_bib5","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1002011","article-title":"Inhibition of mutated, activated BRAF in metastatic melanoma","volume":"363","author":"Flaherty","year":"2010","journal-title":"N Engl J Med"},{"key":"2022061706374151600_bib6","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1203421","article-title":"Improved survival with MEK inhibition in BRAF-mutated melanoma","volume":"367","author":"Flaherty","year":"2012","journal-title":"N Engl J Med"},{"key":"2022061706374151600_bib7","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/nature13572","article-title":"eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies","volume":"513","author":"Boussemart","year":"2014","journal-title":"Nature"},{"key":"2022061706374151600_bib8","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/pcmr.12087","article-title":"The path of least resistance: enhancing the effectiveness of BRAF inhibitors","volume":"26","author":"Goding","year":"2013","journal-title":"Pigment Cell Melanoma Res"},{"key":"2022061706374151600_bib9","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.18632\/oncotarget.1420","article-title":"Mitochondrial oxidative stress is the achille's heel of melanoma cells resistant to Braf-mutant inhibitor","volume":"4","author":"Corazao-Rozas","year":"2013","journal-title":"Oncotarget"},{"key":"2022061706374151600_bib10","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1073\/pnas.1816391116","article-title":"Elucidating cancer metabolic plasticity by coupling gene regulation with metabolic pathways","volume":"116","author":"Jia","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022061706374151600_bib11","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cmet.2015.12.006","article-title":"The emerging hallmarks of cancer metabolism","volume":"23","author":"Pavlova","year":"2016","journal-title":"Cell Metab"},{"key":"2022061706374151600_bib12","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"2022061706374151600_bib13","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/pcmr.12661","article-title":"Metabolic strategies of melanoma cells: mechanisms, interactions with the tumor microenvironment, and therapeutic implications","volume":"31","author":"Fischer","year":"2018","journal-title":"Pigment Cell Melanoma Res"},{"key":"2022061706374151600_bib14","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1101\/sqb.2012.76.010900","article-title":"Metabolic pathway alterations that support cell proliferation","volume":"76","author":"Vander Heiden","year":"2011","journal-title":"Cold Spring Harb Symp Quant Biol"},{"key":"2022061706374151600_bib15","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.cels.2018.06.003","article-title":"Four key steps control glycolytic flux in mammalian cells","volume":"7","author":"Tanner","year":"2018","journal-title":"Cell Syst"},{"key":"2022061706374151600_bib16","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.15252\/embr.201643300","article-title":"PKM2, cancer metabolism, and the road ahead","volume":"17","author":"Dayton","year":"2016","journal-title":"EMBO Rep"},{"key":"2022061706374151600_bib17","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1126\/science.123.3191.309","article-title":"On the origin of cancer cells","volume":"123","author":"Warburg","year":"1956","journal-title":"Science"},{"key":"2022061706374151600_bib18","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.phrs.2016.02.009","article-title":"Targeting metabolic reprogramming as a potential therapeutic strategy in melanoma","volume":"107","author":"Smith","year":"2016","journal-title":"Pharmacol Res"},{"key":"2022061706374151600_bib19","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/nature06734","article-title":"The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth","volume":"452","author":"Christofk","year":"2008","journal-title":"Nature"},{"key":"2022061706374151600_bib20","doi-asserted-by":"crossref","first-page":"5482","DOI":"10.1038\/onc.2015.6","article-title":"Regulatory circuit of PKM2\/NF-\u03baB\/miR-148a\/152-modulated tumor angiogenesis and cancer progression","volume":"34","author":"Xu","year":"2015","journal-title":"Oncogene"},{"key":"2022061706374151600_bib21","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1038\/s41598-017-03031-1","article-title":"PKM2 promotes cell migration and inhibits autophagy by mediating PI3K\/AKT activation and contributes to the malignant development of gastric cancer","volume":"7","author":"Wang","year":"2017","journal-title":"Sci Rep"},{"key":"2022061706374151600_bib22","doi-asserted-by":"crossref","first-page":"16082","DOI":"10.1038\/srep16082","article-title":"Nuclear PKM2 contributes to gefitinib resistance via upregulation of STAT3 activation in colorectal cancer","volume":"5","author":"Li","year":"2015","journal-title":"Sci Rep"},{"key":"2022061706374151600_bib23","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.cellsig.2018.01.021","article-title":"AKT2 contributes to increase ovarian cancer cell migration and invasion through the AKT2-PKM2-STAT3\/NF-\u03baB axis","volume":"45","author":"Zheng","year":"2018","journal-title":"Cell Signal"},{"key":"2022061706374151600_bib24","doi-asserted-by":"crossref","first-page":"e0123830","DOI":"10.1371\/journal.pone.0123830","article-title":"PKM2 subcellular localization is involved in oxaliplatin resistance acquisition in HT29 human colorectal cancer cell lines","volume":"10","author":"Gin\u00e9s","year":"2015","journal-title":"PLoS One"},{"key":"2022061706374151600_bib25","doi-asserted-by":"crossref","first-page":"45983","DOI":"10.1038\/srep45983","article-title":"Inhibition of pyruvate kinase M2 markedly reduces chemoresistance of advanced bladder cancer to cisplatin","volume":"7","author":"Wang","year":"2017","journal-title":"Sci Rep"},{"key":"2022061706374151600_bib26","doi-asserted-by":"crossref","first-page":"e1600200","DOI":"10.1126\/sciadv.1600200","article-title":"Fundamentals of cancer metabolism","volume":"2","author":"De Berardinis","year":"2016","journal-title":"Sci Adv"},{"key":"2022061706374151600_bib27","doi-asserted-by":"crossref","first-page":"2880","DOI":"10.1021\/cr900028p","article-title":"Enzymology of purine and pyrimidine antimetabolites used in the treatment of cancer","volume":"109","author":"Parker","year":"2009","journal-title":"Chem Rev"},{"key":"2022061706374151600_bib28","doi-asserted-by":"crossref","first-page":"688","DOI":"10.3390\/cancers11050688","article-title":"Cancer cells tune the signaling pathways to empower de novo synthesis of nucleotides","volume":"11","author":"Villa","year":"2019","journal-title":"Cancers"},{"key":"2022061706374151600_bib29","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1158\/2159-8290.CD-16-0611","article-title":"Adaptive reprogramming of de novo pyrimidine synthesis is a metabolic vulnerability in triple-negative breast cancer","volume":"7","author":"Brown","year":"2017","journal-title":"Cancer Discov"},{"key":"2022061706374151600_bib30","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.cmet.2018.06.005","article-title":"Inosine monophosphate dehydrogenase dependence in a subset of small cell lung cancers","volume":"28","author":"Huang","year":"2018","journal-title":"Cell Metab"},{"key":"2022061706374151600_bib31","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.ccell.2017.09.013","article-title":"mTORC1 couples nucleotide synthesis to nucleotide demand resulting in a targetable metabolic vulnerability","volume":"32","author":"Valvezan","year":"2017","journal-title":"Cancer Cell"},{"key":"2022061706374151600_bib32","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1021\/acs.jmedchem.6b01803","article-title":"In vitro and in vivo evaluation of fully substituted (5-(3-Ethoxy-3- oxopropynyl)-4-(ethoxycarbonyl)-1,2,3-triazolyl-glycosides as original nucleoside analogues to circumvent resistance in myeloid malignancies","volume":"60","author":"Amdouni","year":"2017","journal-title":"J Med Chem"},{"key":"2022061706374151600_bib33","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1038\/jid.2014.202","article-title":"Inhibition of melanogenesis by the antidiabetic metformin","volume":"134","author":"Lehraiki","year":"2014","journal-title":"J Invest Dermatol"},{"key":"2022061706374151600_bib34","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1158\/1535-7163.MCT-12-1226-T","article-title":"Metformin blocks melanoma invasion and metastasis development in AMPK\/p53-dependent manner","volume":"12","author":"Cerezo","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"2022061706374151600_bib35","doi-asserted-by":"crossref","first-page":"1323\u20148","DOI":"10.1126\/science.1228792","article-title":"Stimulation of de novo pyrimidine synthesis by growth signaling through mTOR and S6K1","volume":"339","author":"Ben-Sahra","year":"2013","journal-title":"Science"},{"key":"2022061706374151600_bib36","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.chembiol.2019.11.010","article-title":"Identification of a small compound targeting PKM2-regulated signaling using 2D gel electrophoresis-based proteome-wide CETSA","volume":"27","author":"Nagasawa","year":"2020","journal-title":"Cell Chem Biol"},{"key":"2022061706374151600_bib37","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1002\/pro.505","article-title":"Human pyruvate kinase M2: a multifunctional protein","volume":"19","author":"Gupta","year":"2010","journal-title":"Protein Sci"},{"key":"2022061706374151600_bib38","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ccell.2016.06.007","article-title":"Compounds triggering ER stress exert anti-melanoma effects and overcome BRAF inhibitor resistance","volume":"30","author":"Cerezo","year":"2016","journal-title":"Cancer Cell"},{"key":"2022061706374151600_bib39","doi-asserted-by":"crossref","first-page":"39473","DOI":"10.18632\/oncotarget.7790","article-title":"Mitochondrial oxidative phosphorylation controls cancer cell's life and death decisions upon exposure to MAPK inhibitors","volume":"7","author":"Corazao-Rozas","year":"2016","journal-title":"Oncotarget"},{"key":"2022061706374151600_bib40","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.cmet.2018.09.001","article-title":"Translational and HIF-1\u03b1-dependent metabolic reprogramming underpin metabolic plasticity and responses to kinase inhibitors and biguanides","volume":"28","author":"Hulea","year":"2018","journal-title":"Cell Metab"},{"key":"2022061706374151600_bib41","doi-asserted-by":"crossref","first-page":"584","DOI":"10.18632\/oncotarget.965","article-title":"Dysfunctional oxidative phosphorylation makes malignant melanoma cells addicted to glycolysis driven by the V600EBRAF oncogene","volume":"4","author":"Hall","year":"2013","journal-title":"Oncotarget"},{"key":"2022061706374151600_bib42","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s12943-017-0667-y","article-title":"ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells","volume":"16","author":"Cesi","year":"2017","journal-title":"Mol Cancer"},{"key":"2022061706374151600_bib43","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.canlet.2018.11.018","article-title":"Metabolic targeting synergizes with MAPK inhibition and delays drug resistance in melanoma","volume":"442","author":"Brummer","year":"2019","journal-title":"Cancer Lett"},{"key":"2022061706374151600_bib44","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ejmech.2017.06.019","article-title":"Covalent inhibitors design and discovery","volume":"138","author":"De Cesco","year":"2017","journal-title":"Eur J Med Chem"},{"key":"2022061706374151600_bib45","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.drudis.2018.01.035","article-title":"Progress with covalent small-molecule kinase inhibitors","volume":"23","author":"Zhao","year":"2018","journal-title":"Drug Discov Today"},{"key":"2022061706374151600_bib46","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nrd3410","article-title":"The resurgence of covalent drugs","volume":"10","author":"Singh","year":"2011","journal-title":"Nat Rev Drug Discov"},{"key":"2022061706374151600_bib47","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1039\/b905821b","article-title":"The topology of drug-target interaction networks: implicit dependence on drug properties and target families","volume":"5","author":"Mestres","year":"2009","journal-title":"Mol Biosyst"},{"key":"2022061706374151600_bib48","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41586-019-1694-1","article-title":"The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity","volume":"575","author":"Canon","year":"2019","journal-title":"Nature"},{"key":"2022061706374151600_bib49","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.cell.2018.01.006","article-title":"Targeting KRAS mutant cancers with a covalent G12C-specific inhibitor","volume":"172","author":"Janes","year":"2018","journal-title":"Cell"},{"key":"2022061706374151600_bib50","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.chembiol.2017.05.023","article-title":"Perspective privileged electrophile sensors: a resource for covalent drug development","volume":"24","author":"John","year":"2017","journal-title":"Cell Chem Biol"},{"key":"2022061706374151600_bib51","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/rcm.885","article-title":"A top down approach to protein structural studies using chemical cross-linking and Fourier transform mass spectrometry","volume":"17","author":"Kruppa","year":"2003","journal-title":"Rapid Commun Mass Spectrom"},{"key":"2022061706374151600_bib52","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.cbpa.2014.10.021","article-title":"Covalent protein modification: the current landscape of residue-specific electrophiles","volume":"24","author":"Shannon","year":"2015","journal-title":"Curr Opin Chem Biol"},{"key":"2022061706374151600_bib53","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/nature18002","article-title":"Proteome wide covalent ligand discovery in native biological systems","volume":"534","author":"Backus","year":"2016","journal-title":"Nature"},{"key":"2022061706374151600_bib54","first-page":"79","article-title":"Exon-centric regulation of pyruvate kinase M alternative splicing via mutually exclusive exons","volume":"4","author":"Krainer","year":"2011","journal-title":"J Mol Cell Biol"},{"key":"2022061706374151600_bib55","doi-asserted-by":"crossref","first-page":"13807","DOI":"10.1016\/S0021-9258(18)67091-7","article-title":"The M1- and M2-type isozymes of rat pyruvate kinase are produced from the same gene by alternative RNA splicing","volume":"261","author":"Noguchi","year":"1986","journal-title":"J Biol Chem"},{"key":"2022061706374151600_bib56","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s13238-015-0132-x","article-title":"Structural insight into mechanisms for dynamic regulation of PKM2","volume":"6","author":"Wang","year":"2015","journal-title":"Protein Cell"},{"key":"2022061706374151600_bib57","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.cell.2013.09.025","article-title":"XPKM2 isoform-specific deletion reveals a differential requirement for pyruvate kinase in tumor cells","volume":"155","author":"Israelsen","year":"2013","journal-title":"Cell"},{"key":"2022061706374151600_bib58","doi-asserted-by":"crossref","first-page":"e0191419","DOI":"10.1371\/journal.pone.0191419","article-title":"Lapachol inhibits glycolysis in cancer cells by targeting pyruvate kinase M2","volume":"13","author":"Babu","year":"2018","journal-title":"PLoS One"},{"key":"2022061706374151600_bib59","doi-asserted-by":"crossref","first-page":"14517","DOI":"10.1038\/s41598-018-31615-y","article-title":"Shikonin inhibits tumor growth in mice by suppressing pyruvate kinase M2-mediated aerobic glycolysis","volume":"8","author":"Zhao","year":"2018","journal-title":"Sci Rep"},{"key":"2022061706374151600_bib60","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.cell.2014.07.048","article-title":"Cell state-specific metabolic dependency in hematopoiesis and leukemogenesis","volume":"158","author":"Wang","year":"2014","journal-title":"Cell"},{"key":"2022061706374151600_bib61","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1084\/jem.20111487","article-title":"Pyruvate kinase M2-specific siRNA induces apoptosis and tumor regression","volume":"209","author":"Goldberg","year":"2012","journal-title":"J Exp Med"},{"key":"2022061706374151600_bib62","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/nchembio.1060","article-title":"Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis","volume":"8","author":"Mattaini","year":"2012","journal-title":"Nat Chem Biol"},{"key":"2022061706374151600_bib63","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1158\/1535-7163.MCT-13-0026","article-title":"Pharmacologic activation of PKM2 slows lung tumor xenograft growth","volume":"12","author":"Foulks","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"2022061706374151600_bib64","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.molcel.2012.01.001","article-title":"Pyruvate kinase M2 regulates gene transcription by acting as a protein kinase","volume":"45","author":"Gao","year":"2012","journal-title":"Mol Cell"},{"key":"2022061706374151600_bib65","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/nature10598","article-title":"Nuclear PKM2 regulates \u03b2-catenin transactivation upon EGFR activation","volume":"480","author":"Yang","year":"2012","journal-title":"Nature"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/81\/14\/3806\/3085635\/3806.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/81\/14\/3806\/3085635\/3806.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T16:24:36Z","timestamp":1655483076000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/81\/14\/3806\/670247\/Dual-Covalent-Inhibition-of-PKM-and-IMPDH-Targets"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,7]]},"references-count":65,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2021,6,7]]},"published-print":{"date-parts":[[2021,7,15]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-20-2114","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.22428496","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22428484","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22428493","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22428487.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22428499","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22428487","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22428484.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22428481","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22428481.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22428490","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6513040","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6513040.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22428502.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22428505","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22428505.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22428499.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22428496.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22428502","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22428490.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22428493.v1","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,7]]}}}